en · de · es · fr · pt
aod-9604-notes.peptides1126.com › News › Identity And Research Origin — Explained

Identity And Research Origin — Explained

By Editorial Desk · published 2025-11-16 · last reviewed 2025-12-04 · News

If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Mechanism And Metabolic Effects

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Related pages on this site

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Background from the literature

== Usage == AUFS is an arbitrary unit of the maximum ultraviolet or visible light absorbance intensity measured by a detector. It can be used in chemical analysis to quantify components in a mixture, as each component's integrated peak area corresponds to their relative abundance. AUFS is given as a number ranging from 0 to 1, where a measurement of 1 AUFS indicates an absorbance reading of 1 at full deflection.

== Signs and symptoms == LNS is characterized by three major hallmarks: neurologic dysfunction, cognitive and behavioral disturbances including self-mutilation, and uric acid overproduction (hyperuricemia). Damage to the basal ganglia causes affected individuals to adopt a characteristic fencing stance due to the nature of the lesion. Some may also have macrocytic anemia due to the faulty DNA synthesis, most likely due to deficient purine synthesis that leads to a lag of cell division with respect to increases in cell mass. Virtually all patients are male; males experience delayed growth and puberty, and most develop shrunken testicles or testicular atrophy. Female carriers are at an increased risk for gouty arthritis but are usually otherwise unaffected.

First, the Citizens Rights Directive 2004 article 4 says every citizen has the right to depart a member state with a valid passport. This has historical importance for central and eastern Europe, when the Soviet Union and the Berlin Wall denied its citizens the freedom to leave. Article 5 gives every citizen a right of entry, subject to national border controls. Schengen Area countries (not the UK and Ireland) abolished the need to show documents, and police searches at borders, altogether. These reflect the general principle of free movement in TFEU article 21. Second, article 6 allows every citizen to stay three months in another member state, whether economically active or not. Article 7 allows stays over three months with evidence of "sufficient resources... not to become a burden on the social assistance system". Articles 16 and 17 give a right to permanent residence after 5 years without conditions. Third, TEU article 10(3) requires the right to vote in the local constituencies for the European Parliament wherever a citizen lives.

==== Privatization of waterways in the North, Recife Metro and COMPESA ==== In June 2025, the Lula government, despite strong popular opposition, supported the privatization of the Recife Metro and of the COMPESA (the Pernambuco sanitation company responsible for water supply in the state), measures announced by the governor of Pernambuco, Raquel Lyra. In both cases, the BNDES, under the leadership of Aloizio Mercadante, organized the studies to make the privatization process feasible and will also conduct the bidding procedures. In late May, the chief of staff, Rui Costa, had already confirmed that the Recife Metro would be privatized, continuing a process initiated in 2019 during the Jair Bolsonaro administration. The argument used by the government to justify the measure is that the metro system generates only financial losses. The decision prompted protests in Pernambuco, especially in Recife. In addition, in September 2025 the government included the waterway of the Madeira River and the waterways of the Tocantins and Tapajós rivers in the National Privatization Program (PND), a measure that also received criticism. During the 2022 presidential campaign and in government, Lula strongly criticized the privatizations carried out by the previous administration and even promised that the Recife Metro would not be privatized. The privatization measures were criticized especially by the more radical sectors of the Brazilian left, which also criticized the government's attempt to soften the term “privatization” by presenting them as “concessions”.

Sources: en.wikipedia.org

Further detail

Plutonium (94Pu) is an artificial element, except for trace quantities resulting from neutron capture by uranium, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no stable isotopes. It was synthesized before being found in nature, with the first isotope synthesized being 238Pu in 1940. Twenty-two plutonium radioisotopes have been characterized. The most stable are 244Pu with a half-life of 81.3 million years, 242Pu with a half-life of 375,000 years, 239Pu with a half-life of 24,110 years, and 240Pu with a half-life of 6,561 years. This element also has eight meta states; all have half-lives of less than one second. The known isotopes of plutonium range from 226Pu to 247Pu. The primary decay modes before the most stable isotope, 244Pu, are spontaneous fission and alpha decay; the primary mode after is beta emission. The primary decay products before 244Pu are isotopes of uranium and neptunium (not considering fission products), and the primary decay products after are isotopes of americium.

Is it morally right to tamper with nature? Is one playing God when creating new life? What happens if a synthetic organism accidentally escapes? What if an individual misuses synthetic biology and creates a harmful entity (e.g., a biological weapon)? Who will have control of and access to the products of synthetic biology? Who will gain from these innovations? Investors? Medical patients? Industrial farmers? Does the patent system allow patents on living organisms? What about parts of organisms, like HIV resistance genes in humans? What if a new creation is deserving of moral or legal status? The ethical aspects of synthetic biology has three main features: biosafety, biosecurity, and the creation of new life forms. Other ethical issues mentioned include the regulation of new creations, patent management of new creations, benefit distribution, and research integrity. Ethical issues have surfaced for recombinant DNA and genetically modified organism (GMO) technologies and extensive regulations of genetic engineering and pathogen research were in place in many jurisdictions. Amy Gutmann, former head of the Presidential Bioethics Commission, argued that we should avoid the temptation to over-regulate synthetic biology in general, and genetic engineering in particular. According to Gutmann, "Regulatory parsimony is especially important in emerging technologies...where the temptation to stifle innovation on the basis of uncertainty and fear of the unknown is particularly great.

Dayhoff was born an only child in Philadelphia, but moved to New York City when she was ten. Her academic promise was evident from the outset – she was valedictorian (class of 1942) at Bayside High School, Bayside, New York, and from there received a scholarship to Washington Square College of New York University, graduating magna cum laude in mathematics in 1945 and getting elected to Phi Beta Kappa.

Sources: en.wikipedia.org

Background from the literature

== Contraindications == Circumcision is contraindicated in certain cases. These include infants with certain genital structure abnormalities, such as a misplaced urethral opening (as in hypospadias and epispadias), curvature of the head of the penis (chordee), or ambiguous genitalia, because the foreskin may be needed for reconstructive surgery. Circumcision is contraindicated in premature infants and those who are not clinically stable and in good health. If a person is known to have or has a family history of serious bleeding disorders such as hemophilia, it is recommended that the blood be checked for normal coagulation properties before the procedure is attempted.

1885: Berries from Norfolk, Virginia, were shipped by refrigerator car to New York. 1887: Parker Earle joined F.A. Thomas of Chicago in the fruit shipping business. The company owned 60 ice-cooled railcars by 1888, and 600 by 1891. 1888: Armour & Co. shipped beef from Chicago to Florida in a car cooled by ethyl chloride-compression machinery. Florida oranges were shipped to New York under refrigeration for the first time. 1889: The first cooled shipment of fruit from California was sold on the New York market. 1898: Russia's first refrigerator cars entered service. The country's inventory reached 1,900 by 1908, 3,000 two years later, and peaked at approximately 5,900 by 1916. The cars were used mainly for transporting butter from Siberia to the Baltic Sea, a 12-day journey. 1899: Refrigerated fruit traffic within the U.S. reached 90,000 short tons (81,647 t; 80,357 long tons) per year; Transport from California to New York averaged 12 days in 1900. 1901: Carl von Linde equipped a Russian train with a mobile, central mechanical refrigeration plant to distribute cooling to cars carrying perishable goods. Similar systems were used in Russia as late as 1975. 1905: U.S. traffic in refrigerated fruit reached 430,000 short tons (390,089 t; 383,929 long tons). As refrigerator car designs became standardized, the practice of indicating the "patentee" on the sides was discontinued. 1907: The Pacific Fruit Express began operations with more than 6,000 refrigerated cars, transporting fruit and vegetables from Western producers to Eastern consumers. U.S.

=== Splitting monolayer carbon allotropes === Graphene can be created by opening carbon nanotubes by cutting or etching. In one such method, multi-walled carbon nanotubes were cut open in solution by action of potassium permanganate and sulfuric acid. In 2014, carbon nanotube-reinforced graphene was made via spin coating and annealing functionalized carbon nanotubes. Another approach sprays buckyballs at supersonic speeds onto a substrate. The balls cracked open upon impact, and the resulting unzipped cages then bond together to form a graphene film.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

How is AOD-9604 thought to work?

It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.

Network